User discovered hair fibers, tried Toppik but concerned about ingredients. Considering Boldify (cotton-based, cheaper) and Surethik (keratin-based) as better options.
Orsobalorso took 2.5mg oral minoxidil daily for a year but saw little improvement and stopped due to potential side effects and cost. They also tried finasteride, dutasteride, dermarolling, RU58841, keto, alfatradiol, and stemoxydine, with mild improvement from finasteride.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
The user is experiencing painful side effects from finasteride and is considering switching to oral minoxidil and biotin to maintain their hair. They are seeking advice on whether this change would help preserve their current hair.
RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.
The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.
The conversation is about compounding topical cyclosporine for hair loss, suggesting it needs an oil base like castor oil. The user seeks tips or tricks for the process.
A user with seborrheic dermatitis uses Ketoconazole 2% and Betamethasone and is considering starting Minoxidil for thinning hair. They are concerned about using Minoxidil and Betamethasone simultaneously.
The user has been using 5mg Minoxidil, 1.1mg Finasteride, and 1mg Biotin for four months to address hair loss. They haven't noticed significant improvement yet but are documenting progress with monthly pictures.
The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.
The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.
The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.
A user is considering switching from regular 5% minoxidil foam to a compounded 5% minoxidil spray with added caffeine, melatonin, and tretinoin for easier application and potentially better results. Another user mentions that tretinoin can enhance minoxidil's effectiveness by converting it to its active form.
The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
Batana oil is gaining attention for hair growth, but users suggest Minoxidil as more effective. Some recommend using both Batana and Rosemary oil for better results, though skepticism about viral claims exists.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
The conversation is about someone planning to use cb-03-01 for hair loss because they experience side effects with other treatments like finasteride, minoxidil, and RU58841. They have not found progress pictures online and are considering sharing their own experience with cb-03-01, which is expensive.
The user mixed Pyrilutamide with a KB solution and noticed some undissolved powder, questioning if more shaking or liquid is needed. They use Pyrilutamide from Anagenic.
The user has been using oral minoxidil (5mg), finasteride (1mg), and biotin for 4 months with minimal progress in hair regrowth. Other users suggest patience, considering alternative treatments, and note that biotin may not significantly contribute unless there's a deficiency.
PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.
Bimatoprost 1% and 3% solutions showed better hair regrowth than minoxidil 5%. The user plans to test a homemade bimatoprost solution on their scalp and share results.
Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.
The user felt pressured during a hair transplant consultation at Bosley, where they were advised to undergo FUT surgery and use a laser cap for maintenance, but did not meet with a doctor. Other users recommended seeking a second opinion from reputable doctors like Dr. Rassman and suggested trying finasteride first.
The user is using a topical solution with finasteride, minoxidil, and tretinoin and is considering adding GHK-Cu to enhance hair growth and quality. Another user suggests diluting GHK-Cu and storing it in a smaller, refrigerated bottle.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
A user created oral minoxidil sugar cubes due to lack of prescription access, leading to a humorous discussion about unconventional and potentially unsafe methods of using minoxidil. The conversation highlights the lengths people go to for hair growth.
Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.